真实生物第三次赴港IPO,两年来累计研发投入4.43亿元

大河财立方
Nov 10, 2025

【大河财立方 记者 王磊彬】11月10日,真实生物科技有限公司(以下简称真实生物)递表港交所主板,这是继2022年8月、2025年2月之后,第三次申请在港交所上市。根据弗若斯特沙利文的资料,由真实生物研发生产的阿兹夫定,具有广谱抗病毒活性,是全球唯一一款用于治疗HIV的双靶点口服核苷药物,目前已经覆盖了全国31个省市区超过50000家医疗终端。真实生物第三次赴港上市阿兹夫定已累计销售超过1000...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10